Introduction
In November 2009, all medications containing benfluorex were withdrawn from drug market in France. This treatment, still consumed until recently by 300 000 French inhabitants 1 for treatment of overweight diabetic patients and dyslipidemia, has been suspected to cause valvular disease 1 -3 and pulmonary arterial hypertension. 4 Like other appetite suppressants (fenfluramine and dexfenfluramine 5 -9 ), benfluorex would induce valvular abnormalities similar to those observed in carcinoid heart valve disease. 10 Norfenfluramine, a metabolite of benfluorex, interacts with the 5HT-2B serotonin receptor 11 and activates fibroblasts proliferation. 12 Stimulation of 5HT-2B receptors, which are present in great quantity on the aortic and mitral valves, induces valvular fibrosis, loss of flexibility of the leaflets, and restriction of their movement. Two recent case-control studies reported that unexplained restrictive mitral regurgitation was more frequently observed in patients exposed to benfluorex than in controls.
1,2 A recent registry reported 40 cases of unexplained restrictive valvular disease in patients previously treated with benfluorex. 3 However, these studies included only a limited number of patients and many uncertainties persist concerning incidence, diagnosis, and prognosis of this form of valvular disease.
The aim of our study was to assess the frequency of benfluorex exposure in patients with restrictive mitral or aortic valve disease and to describe their echocardiographic characteristics.
Methods

Patient population
We performed a retrospective study in the laboratory of echocardiography of the department of cardiology of Marseille. All echocardiographic reports from January 2005 to December 2010 describing an unexplained restrictive organic aortic or mitral disease were selected. Mitral or aortic regurgitation was considered to be restrictive in the presence of a reduced valvular mobility associated with variable degrees of valvular thickening. 2 Only the patients whose restrictive valvular disease did not have an identifiable aetiology were included. Patients in which a clear cause of valve disease was identified were excluded, i.e. valvular regurgitation with structurally normal valve (ischaemic chronic heart disease or dilated cardiomyopathy, hypertrophic cardiomyopathy, or dilation of the ascending aorta), organic valve disease caused by another aetiology (previous rheumatic fever, infective endocarditis, radiation therapy, carcinoid disease), valve heart disease associated with vasculitis or connective disease, and congenital anomalies (bicuspid aortic valve). 3 The other patients were regarded as having an unexplained restrictive valvular pathology and were included. Finally, only patients presenting with a valvular regurgitation of at least moderate severity were included.
Clinical data
All these patients were contacted by phone call by the same observer (A.B.). The following data were collected: cardiovascular risk factors, symptoms at the time of echography, patient's height and weight, medical history, occurrence of cardiovascular events since the first echocardiographic examination, exposure to drugs potentially causing valvular heart disease [appetite-suppressants drugs, ergot alkaloids, dopamine agonists (Parkinson's disease), cabergolide 13 -17 ]. Concerning anorectic agents, daily and cumulated doses of benfluorex and other drugs were noticed when available, as well as total treatment duration and indication. When the patient was not reached or dead, his/her family or general practitioner was contacted.
Finally, patients were separated into two groups depending on their anorectic drug consumption or not:
-patients never treated with appetite-suppressant drugs (ASDs); -patients with previous exposure to benfluorex combined or not with another anorectic drug; -among the latter, patients exposed to benfluorex only were separately studied.
Doppler echographic data
All echocardiographic examinations were performed in the echo lab by a senior echocardiographist. Conventional 2D echocardiography was performed using commercially available equipment (Vivid-7 or Vivid-9, General Electric Medical Systems, Horten, Norway or Sonos 7500 (Philips, Andover, MA, USA) ultrasound system and were stored in digital format for subsequent analysis. Data were acquired with an M3S 3. 
Results
Patients
Between 1 January 2005 and 31 August 2010, 130 echocardiographic reports identified an unexplained restrictive mitral or aortic disease. Among them, 83 had to be excluded because another cause of valve involvement was identified after review of the hospitalization report and/or phone discussion with the patient or his general practitioner (n ¼ 43), because the echocardiographic records were not available for a second review (n ¼ 20) or because the second review of the data did not confirm the initial diagnosis of restrictive valve disease with at least moderate valve regurgitation (n ¼ 20).
Finally, 47 patients (42 women) presenting an unexplained restrictive valve disease were observed. The clinical features of these patients are presented in Table 1 . Among them, 35 (74%) had had previous treatment with ASDs, including benfluorex in the majority of them (n ¼ 34). Among these 34 patients, 14 (40%) have been treated with benfluorex alone, 20 (60%) in combination with another ASD mainly dexfenfluramine ( Figure 1 ). Only 1 patient has been treated with fenfluramine alone and 12 patients (26%) denied any anorectic treatment.
Echocardiography
Echocardiographic characteristics are summarized in Table 2 . On the mitral valve, thickened mitral leaflets with limited systolic excursion were observed in all patients, associated with subvalvular involvement (thickened chordate tendinae) in the majority of them. Mitral involvement resulted in mitral regurgitation in the Valvular heart disease associated with benfluorex therapy majority of cases (n ¼ 37). In the most severe forms, mitral involvement was associated with reduced leaflet coaptation. Mitral stenosis (mitral area ,1.5 cm 2 ) was observed in only eight patients.
Mean mitral gradient ranged from 6 to 10 mmHg in these patients. However, mitral stenosis was always associated with at least moderate mitral regurgitation and mitral area was never ,1 cm 2 . Interestingly, commissural fusion and valve calcification were never observed in these patients.
Similarly, the involvement of the aortic valve consisted of leaflet thickening and restricted motion leading to aortic regurgitation in most cases (n ¼ 36), associated with mitral regurgitation in 28 (60%) patients.
Among the 28 patients with combined mitral and aortic regurgitation with restricted valve motion, 27 (96%) had been exposed to benfluorex, isolated (n ¼ 12) or in combination with another ASD (n ¼ 15) (Figure 2) . Representative echocardiographic examples are presented in Figures 3 and 4 and in see Supplementary data online, Movies 1 -5.
Comparison of patients treated by benfluorex to other restrictive valve disease without anorectic therapy Tables 1 and 2 compare the clinical and echocardiographic features, respectively, of the 34 patients treated by benfluorex and other anorectic drugs to the 12 patients never exposed to anorectic therapy. As compared with the 'no anorexigen' group, patients in the benfluorex group were more frequently female, had more frequent arterial hypertension and hypertriglyceridemia, and presented more frequently with combined mitral and aortic disease (79 vs. 8%, P , 0.001). Thus, the most typical echocardiographic feature of anorexigen valve disease was the presence of both aortic and mitral restrictive valve disease ( Figures 3 and 4 , see Supplementary data online, Movies 1-5).
No other difference was observed between groups concerning valve regurgitation severity. Valve stenosis and moderate or severe tricuspid regurgitation were rare in both groups.
Similar results were obtained when the 14 patients treated by benfluorex only were compared with the 12 patients never exposed to anorectic therapy (Tables 3 and 4 ).
Follow-up
During a mean follow-up of 1.89 + 1.53 years, 13 patients presented at least an event, including 12 surgical treatments, 2 cardiac failures, and 1 death, without differences between groups ( Table 1) . In all operated patients, the macroscopical aspect of the valves was identical, including valvular thickening, glistening white appearance, and retraction of the leaflets both in the aortic and mitral positions. Commissural fusion was not observed on the mitral valve. Histopathological examination of the explanted valves revealed endocardial valvular fibrosis without calcification. Valvular heart disease associated with benfluorex therapy A. Boudes et al.
Discussion
The main findings from this study are the followings:
(1) The frequency of ASDs exposure is very high in patients with unexplained left heart restrictive valvular regurgitation. (2) The most typical echocardiographic findings suggestive of anorectic drugs induced valvular disease is the presence of a combined aortic and mitral restrictive valve regurgitation. (3) Although benfluorex exposure is frequently observed in patients with restrictive valvular regurgitation, multiple drugs exposure is more frequently observed than isolated benfluorex exposure in these patients.
Anorectic drugs induced valvular disease
Fenfluramine and its derivative dexfenfluramine are known to cause valvular disease. 5 -9 Fenfluramine is a sympathomimetic amine with anorectic action mediated through the activation of serotonin pathways in the brain. Fenfluramine promotes the rapid release of serotonin, inhibits its reuptake, and may have receptor-agonist activity thus making serotonin more susceptible to metabolism and breakdown. 20 The d-isomer of fenfluramine, dexfenfluramine, appears to be relatively selective for the central serotonergic system. Both fenfluramine and dexfenfluramine can activate in an excessive way the 5HT-2B serotonin receptor present on the cardiac valves, may induce fibroblasts proliferation and finally restrictive valve disease. 21, 22 Shively et al. in 1999 23 calculated the prevalence of appearance of a mitral or aortic valvular disease among patients exposed to the dexfenfluramine and in controls and found an increase risk of valve regurgitation in the exposed patients (OR ¼ 3.82).
Valvular disease associated with benfluorex exposure
Benfluorex belongs to the amphetamines family. Similar to dexfenfluramine, it interferes with the metabolism of serotonin and activates the 5-HT(2B) receptor by its metabolite, norfenfluramine.
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However, although benfluorex has recently been reported to cause valvular lesions similar to those observed with the appetitesuppressants fenfluramine and dexfenfluramine, reported series are very scarce. Two recent case-control studies reported that unexplained restrictive mitral regurgitation was more frequently observed in patients exposed to benfluorex than in controls. 1, 2 In these studies however, the number of patients included was small, and only restrictive mitral regurgitation were studied, not aortic regurgitation. In addition, in these studies, patient's characteristics were compared with dystrophic mitral regurgitation 2 or with mitral regurgitation from various aetiologies. 1 In our study, both patients with unexplained restrictive aortic and mitral valve disease were studied, giving the opportunity to describe the frequency of benfluorex exposure in these patients. The main result is that the frequency of benfluorex exposure was very high in patients with left heart restrictive valvular regurgitation. Among the 47 patients studied, 34 (72%) had previous exposure with benfluorex. In addition, an important finding from our study is that multiple drugs exposure was more frequently observed than isolated benfluorex exposure in these patients. Among the 34 patients previously treated with benfluorex, 14 (40%) have been treated with benfluorex alone, 20 (60%) in combination with another appetitesuppressant drug, mainly dexfenfluramine. Consequently, a direct causal relationship between benfluorex therapy and restrictive valve disease may be particularly difficult to affirm in these patients.
Echocardiographic findings
The main echocardiographic abnormalities observed in association with benfluorex therapy have been clearly described in the recent French registry. 3 In these series of 40 cases of aortic or mitral unexplained restrictive valve disease, the main echocardiographic findings were leaflets thickening and retraction, resulting in loss Valvular heart disease associated with benfluorex therapy of coaptation and predominant regurgitation. Mitral and aortic regurgitations were the most frequent, and valve stenoses and tricuspid involvement were rare. 3 Concerning mitral involvement, sub-valvular apparatus is frequently thickened and shortened with fused chordae tendineae, similar to that observed in rheumatic disease. 3 However, two echocardiographic findings are useful to differentiate appetite-suppressant associated valve disease from a rheumatic involvement, i.e. the absence or paucity of commissural fusion and of valve calcification. Similar results were found in our study, with a large predominance of mitral (87%) and aortic (89%) regurgitation in the benfluorex group. In addition, our study gave us the opportunity to compare the clinical and echocardiographic characteristics of patients with restrictive valve disease associated with benfluorex exposure to patients with restrictive valve disease but without anorectic drug exposure. As compared with the 'no anorexigen' group (n ¼ 12), patients in the benfluorex group (n ¼ 34) were more frequently female, had more frequent arterial hypertension and hypertriglyceridemia, and presented more frequently with combined mitral and aortic disease (79 vs. 8%, P , 0.001). As a consequence, the finding of a combined mitral and aortic regurgitation of restrictive mechanism in a hypertensive woman is highly suggestive of valve disease associated with benfluorex or other appetite-suppressant drug.
Limitations of the study
Our study shares the limitations of all retrospective studies. The duration and doses of anorectic treatment could not be reliably obtained in all patients. In addition, although the echocardiographic records were analysed by two observers, the diagnosis is sometimes difficult and frequently subjective. Moreover, only patients presenting with at least moderate regurgitation were included. The diagnosis of appetite-suppressant-associated valve disease in the presence of only minimal regurgitation might be even more difficult. In addition, although no patient reported previous rheumatic disease history, this diagnosis cannot be completely ruled out by the simple interrogation of the patient. Another limitation of the study is the absence of a control group. Comparison with patients with an identified cause of organic of functional mitral disease has already been performed by others. 1, 2 Comparison with a group of patients with restrictive mitral disease due to a known cause has never been performed and would be useful. Finally, our study is descriptive and does not allow proving a direct relationship between drug consumption and presence of a valve disease, even in case of typical echocardiographic findings.
Conclusion
The frequency of benfluorex exposure is very high in patients with left heart restrictive valvular regurgitation. The finding of a mitral or aortic regurgitation of restrictive mechanism without classical causes of valve disease is associated with and might be related to previous exposure with benfluorex or other ASDs. The finding of a combined mitral and aortic regurgitation of restrictive mechanism in a hypertensive woman is highly suggestive and may alert the clinician about the possibility of a valve disease associated with benfluorex or other ASD.
